他汀类药物与银屑病:EADV银屑病工作组立场声明
欧洲皮肤病与性病学会银屑病工作组通过两阶段研究(系统综述与两轮Delphi)制定共识,形成47条概念与推荐,涵盖心血管风险评估、LDL-c阈值、他汀处方与随访等,以帮助皮肤科医生管理中重度银屑病患者的血脂异常并降低心血管风险。
要点
- 银屑病与心血管疾病死亡率增加相关,呈剂量-反应关系。
- 工作组形成47条概念与推荐,涉及风险评估、他汀处方与随访。
- 声明旨在帮助皮肤科医生系统管理银屑病患者的血脂异常。
核心结论
- 应用该立场声明有助于皮肤科医生管理血脂异常并帮助银屑病患者降低心血管风险。
研究设计与样本
- 欧洲皮肤病与性病学会银屑病工作组开展两阶段研究:第一阶段系统综述识别概念与推荐,第二阶段两轮Delphi评估非指南直接来源的推荐。
主要发现
- 共形成47条概念与推荐,包括6条心血管风险与银屑病主要概念、6条LDL-c作用与他汀获益条目、8条心血管风险评估推荐、3条非侵入性心血管影像作用、3条LDL-c阈值、8条他汀处方关键点、10条他汀治疗随访、3条患者转诊专科。
临床怎么用
- 为参与中重度银屑病治疗的皮肤科医生提供系统化血脂异常治疗与转诊决策工具。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis is associated with an increased mortality risk, with cardiovascular disease being the leading excess cause (in a dose-response manner with psoriasis severity). Statins have demonstrated a reduction in all-cause mortality with no excess of adverse events among the general population. The underuse of interventions in cardiovascular prevention, such as statins, for patients with psoriasis may be the result of an insufficient evaluation. OBJECTIVES: To provide the dermatologist with a tool for systematizing the treatment of dyslipidemia in psoriasis, which generally escapes the scope of dermatological practice, and to facilitate decision-making about the referral and treatment of patients. METHODS: The Psoriasis Task Force of the European Academy of Dermatology and Venereology performed this two-phase study to achieve a consensus and create recommendations on the use of statin therapy in patients with psoriasis. The first phase included a systematic review to identify a list of outline concepts and recommendations according to guidelines. The second phase consisted in a two-round Delphi study to evaluate those recommendations not literally taken from guidelines. RESULTS: A list of 47 concepts and recommendations to be followed by dermatologists involved in the treatment of patients with moderate-severe psoriasis was created. It included six main concepts about cardiovascular risk and psoriasis, six items related with the role of low-density lipoprotein cholesterol (LDL-c) and the benefits of statin treatment in psoriasis patients, eight recommendations about how cardiovascular risk should be assessed, three on the role of non-invasive cardiovascular imaging, three on LDL-c thresholds, eight key points related to statin prescription, 10 on statin treatment follow-up and three on patient referral to another specialist. CONCLUSIONS: The application of this position statement (close final list of concepts and recommendations) will help dermatologists to manage dyslipidemia and help psoriasis patients to reduce their cardiovascular risk.
引用
- Gonzalez-Cantero A, Boehncke WH, De Sutter J, et al. Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Academy of Dermatology and Venerology. J Eur Acad Dermatol Venereol. 2023. PMID: 37259959. doi:10.1111/jdv.19191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。